The adrenergic system in pulmonary arterial hypertension: Bench to bedside (2013 Grover conference series)

16Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

In heart failure with reduced left ventricular ejection fraction (HFrEF), adrenergic activation is a key compensatory mechanism that is a major contributor to progressive ventricular remodeling and worsening of heart failure. Targeting the increased adrenergic activation with β-adrenergic receptor blocking agents has led to the development of arguably the single most effective drug therapy for HFrEF. The pressure-overloaded and ultimately remodeled/failing right ventricle (RV) in pulmonary arterial hypertension (PAH) is also adrenergically activated, which raises the issue of whether an antiadrenergic strategy could be effectively employed in this setting. Anecdotal experience suggests that it will be challenging to administer an antiadrenergic treatment such as a β-blocking agent to patients with established moderate-severe PAH. However, the same types of data and commentary were prevalent early in the development of β-blockade for HFrEF treatment. In addition, in HFrEF approaches have been developed for delivering β-blocker therapy to patients who have extremely advanced heart failure, and these general principles could be applied to RV failure in PAH. This review examines the role played by adrenergic activation in the RV faced with PAH, contrasts PAH-RV remodeling with left ventricle remodeling in settings of sustained increases in afterload, and suggests a possible approach for safely delivering an antiadrenergic treatment to patients with RV dysfunction due to moderate-severe PAH.

References Powered by Scopus

Survival in patients with primary pulmonary hypertension: Results from a national prospective registry

3182Citations
N/AReaders
Get full text

Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure

2888Citations
N/AReaders
Get full text

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

2523Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Autonomic nervous system involvement in pulmonary arterial hypertension

102Citations
N/AReaders
Get full text

Bisoprolol in idiopathic pulmonary arterial hypertension: An explorative study

89Citations
N/AReaders
Get full text

Use of β-Blockers in Pulmonary Hypertension

61Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bristow, M. R., & Quaife, R. A. (2015). The adrenergic system in pulmonary arterial hypertension: Bench to bedside (2013 Grover conference series). Pulmonary Circulation, 5(3), 415–423. https://doi.org/10.1086/682223

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘22‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

76%

Researcher 2

12%

Professor / Associate Prof. 1

6%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

44%

Agricultural and Biological Sciences 3

19%

Biochemistry, Genetics and Molecular Bi... 3

19%

Psychology 3

19%

Save time finding and organizing research with Mendeley

Sign up for free
0